- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05954455
Exploring Bulbar Function, Speech And Communication Development in SMA Type 1 (ExSpAnD SMA)
Exploring Bulbar Function, Speech And Communication Development in SMA Type 1 (ExSpAnD SMA)
Study Overview
Status
Conditions
Detailed Description
Study design: observational longitudinal study. In the first instance, this is intended as a single-centre pilot study with a total duration of 3 years. A larger longitudinal study in a wider national and international cohort will be planned according to preliminary results and insights from this pivotal study. The first appointment will be the screening visit. Initially the trial will be discussed, and informed consent will be obtained for participation in the trial. Information will be collected from the patient and their family including demographics, medical history and detail on medications used by the patient. The investigator will discuss and obtain information on feeding and nutritional support required by the patient, speech and language interventions in place including if they are an augmentative alternative communication user and/or eye tracking device user. After this the investigator will be able to confirm eligibility for the trial. The second visit is the baseline, during this a set of assessments will take place to establish the patients' baseline function. This will include a bulbar function assessment (speech and swallowing), a speech and communication assessment and a cognitive assessment (Thinking abilities; memory, language, reasoning and perception). The investigator will collect further data on respiratory function (breathing) and gross motor function (Muscle strength and abilities). The investigator will assess any adverse events which have occurred since the last visit including symptoms, signs, illness etc. There are further tests which could take place at this visit which are an optional part of the study these include event-related potentials, Brain scan (MRI) and additional communication tests. Patients will then be seen at 6 monthly intervals, at 6m, 12m, 18m, 24m, 30m and 36 months. At each of these appointments and changes to medications will be documented. The investigator will discuss and obtain information on feeding and nutritional support required by the patient, speech and language interventions in place including if they are an augmentative alternative communication user and/or eye tracking device user. Assessments which took place at baseline will be repeated including a bulbar function assessment (speech and swallowing), a speech and communication assessment and we will collect data on respiratory function (breathing) and gross motor function (muscle strength and abilities). Cognitive testing will occur at visits at 12, 24 and 36 months.
At all visits the investigator will assess any adverse events which have occurred since the last visit including symptoms, signs, illness etc. If patients have decided to take part in additional cognitive testing, then this will occur at each 6 monthly visit. The month 36 visit will be the end of study visit so as well as the above will include repeat testing of the optional event-related potentials and brain scan (MRI).
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Giovanni Baranello, MD
- Phone Number: 02079052872
- Email: g.baranello@ucl.ac.uk
Study Contact Backup
- Name: Marta Zancolli, PhD
- Phone Number: 02079052188
- Email: m.zancolli@ucl.ac.uk
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- genetic documentation of 5q SMA;
- onset of clinical signs and symptoms at ≤ 6 months (180 days) of age;
- 0 - 18 years of age
- treatment with any of the approved disease-modifying therapies;
- parent(s)/legal guardian(s) willing and able to complete the informed consent process and comply with study procedures and visit schedule.
Exclusion criteria:
- any clinically significant medical finding that - in the judgment of the Investigator - will make the patient unsuitable for participation in, and/or unable to complete the study procedures;
- parent(s)/legal guardian(s) unable or unwilling to comply with study procedures and/or refuses to sign consent form.
Exclusion Criteria:
- any clinically significant medical finding that - in the judgment of the Investigator - will make the patient unsuitable for participation in, and/or unable to complete the study procedures;
- parent(s)/legal guardian(s) unable or unwilling to comply with study procedures and/or refuses to sign consent form.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bulbar function - Changes from baseline
Time Frame: Baseline, Visit Month 12, Month 24, and Months 36
|
Paediatric-Functional Oral Intake Scale (p-FOIS)
|
Baseline, Visit Month 12, Month 24, and Months 36
|
Bulbar function
Time Frame: Visit Month 6
|
Paediatric-Functional Oral Intake Scale (p-FOIS)
|
Visit Month 6
|
Bulbar function
Time Frame: Visit Month 18
|
Paediatric-Functional Oral Intake Scale (p-FOIS)
|
Visit Month 18
|
Bulbar function
Time Frame: Visit Month 30
|
Paediatric-Functional Oral Intake Scale (p-FOIS)
|
Visit Month 30
|
Speech and Communication - Changes from baseline
Time Frame: Baseline, Month 12, Month 24, and Months 36
|
MacArthur-Bates Communicative Development Inventory (MCDI) - Words and Gestures or Words and Sentences
|
Baseline, Month 12, Month 24, and Months 36
|
Speech and Communication
Time Frame: Visit Month 6
|
MacArthur-Bates Communicative Development Inventory (MCDI) - Words and Gestures or Words and Sentences
|
Visit Month 6
|
Speech and Communication
Time Frame: Visit Month 18
|
MacArthur-Bates Communicative Development Inventory (MCDI) - Words and Gestures or Words and Sentences
|
Visit Month 18
|
Speech and Communication
Time Frame: Visit Month 30
|
MacArthur-Bates Communicative Development Inventory (MCDI) - Words and Gestures or Words and Sentences
|
Visit Month 30
|
Speech and Communication - Changes from baseline
Time Frame: Baseline, Visit Month 6, Month 12, Month 18, Month 24, Month 30 and Months 36
|
Peabody Picture Vocabulary Test (PPVT)
|
Baseline, Visit Month 6, Month 12, Month 18, Month 24, Month 30 and Months 36
|
Speech and Communication
Time Frame: Visit Month 6
|
Peabody Picture Vocabulary Test (PPVT)
|
Visit Month 6
|
Speech and Communication
Time Frame: Visit Month 18
|
Peabody Picture Vocabulary Test (PPVT)
|
Visit Month 18
|
Speech and Communication
Time Frame: Visit Month 30
|
Peabody Picture Vocabulary Test (PPVT)
|
Visit Month 30
|
Speech and Communication - Changes from Baseline
Time Frame: Baseline, Month 12, Month 24, and Months 36
|
Social Communication Questionnaire (SCQ)
|
Baseline, Month 12, Month 24, and Months 36
|
Speech and Communication
Time Frame: Visit Month 6
|
Social Communication Questionnaire (SCQ)
|
Visit Month 6
|
Speech and Communication
Time Frame: Visit Month 18
|
Social Communication Questionnaire (SCQ)
|
Visit Month 18
|
Speech and Communication
Time Frame: Visit Month 30
|
Social Communication Questionnaire (SCQ)
|
Visit Month 30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive function - Changes from baseline
Time Frame: Baseline, Month 12, Month 24, and Months 36
|
Bayley Scales of Infant Development - Third Edition (Bayley-III)
|
Baseline, Month 12, Month 24, and Months 36
|
Cognitive function
Time Frame: Visit Month 6
|
Bayley Scales of Infant Development - Third Edition (Bayley-III)
|
Visit Month 6
|
Cognitive function
Time Frame: Visit Month 18
|
Bayley Scales of Infant Development - Third Edition (Bayley-III)
|
Visit Month 18
|
Cognitive function
Time Frame: Visit Month 30
|
Bayley Scales of Infant Development - Third Edition (Bayley-III)
|
Visit Month 30
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 19NM18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SMA1
-
IRCCS Fondazione Stella MarisFondazione Policlinico Universitario Agostino Gemelli IRCCS; Fondazione IRCCS...Enrolling by invitationCerebral Palsy | Motor Outcome | SMA1 | EEG Sleep SpindlesItaly